BRIEF-Thrombogenics says Jetrea drug gains approval in Argentina, Israel

jueves 12 de febrero de 2015 03:22 GYT

Feb 12 (Reuters) - Thrombogenics NV :

* Announces that Jetrea (Ocriplasmin) has gained approval in Argentina and Israel

* Thrombogenics' partner Alcon, which is commercializing Jetrea outside the US, will be responsible for the launch of the drug in Argentina and Israel.

* Jetrea has been indicated for the treatment of adults with vitreomacular traction (VMT) Source text: ( Further company coverage: (Bengaluru Newsroom; +44 207 542 1810)